TLSA Profile
Tiziana Life Sciences Ltd is a biotechnology company specializing in the discovery and development of innovative therapies for oncology and immunology. The company focuses on creating novel molecules to address a range of human diseases. Tiziana's lead product candidate in the immunology sector is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) designed to target and modulate the immune system. Foralumab is being developed for the treatment of several conditions, including Crohn's disease, graft-versus-host disease, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel disease, psoriasis, and rheumatoid arthritis. This broad therapeutic focus aims to address autoimmune and inflammatory disorders through targeted immune modulation.
In the oncology domain, Tiziana Life Sciences is advancing Milciclib (TZLS-201), a small-molecule inhibitor that targets various cyclin-dependent kinases (CDKs), tropomycin receptor kinases (TRKs), and Src family kinases. This compound is designed to interfere with cellular processes that drive cancer growth and progression. By inhibiting these key enzymes, Milciclib aims to provide a new approach to cancer treatment, particularly for malignancies characterized by uncontrolled cell proliferation.
Another significant development in Tiziana's pipeline is the anti-Interleukin 6 receptor (IL6R) monoclonal antibody (TZLS-501). This fully human mAb targets the IL6R pathway, which is involved in inflammation and has been implicated in various disease states, including COVID-19. TZLS-501 is being explored for its potential to mitigate IL6-induced inflammation and provide therapeutic benefits in treating COVID-19 patients, reflecting the company's commitment to addressing emerging health challenges.
Established in 1998 and headquartered in London, United Kingdom, Tiziana Life Sciences Ltd continues to advance its research and development efforts to bring forward transformative therapies. The company's focus on cutting-edge science and its diverse pipeline of therapeutic candidates underscore its dedication to addressing significant unmet medical needs in both oncology and immunology.
|
